Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344597 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL8590554 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL5350100 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL5390328 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7026542 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL3546297 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL3570498 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL7154349 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6949988 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 | |
| SCHEMBL6956183 | 1.00 | PTPN1 (0.44) | PTPN1POLBGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | PTPN1 1541/4885POLB 3144/4885GAA 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.